Itraconazole inhibits endothelial cell migration by disrupting inositol pyrophosphate-dependent focal adhesion dynamics and cytoskeletal remodeling - 28/03/23

Abstract |
The antifungal drug itraconazole has been repurposed to anti-angiogenic agent, but the mechanisms of action have been elusive. Here we report that itraconazole disrupts focal adhesion dynamics and cytoskeletal remodeling, which requires 5-diphosphoinositol 1,2,3,4,6-pentakisphosphate (5-InsP7). We find that inositol hexakisphosphate kinase 1 (IP6K1) binds Arp2 and generates 5-InsP7 to recruit coronin, a negative regulator of the Arp2/3 complex. IP6K1 also produces focal adhesion-enriched 5-InsP7, which binds focal adhesion kinase (FAK) at the FERM domain to promote its dimerization and phosphorylation. Itraconazole treatment elicits displacement of IP6K1/5-InsP7, thus augments 5-InsP7-mediated inhibition of Arp2/3 complex and reduces 5-InsP7-mediated FAK dimerization. Itraconazole-treated cells display reduced focal adhesion dynamics and actin cytoskeleton remodeling. Accordingly, itraconazole severely disrupts cell motility, an essential component of angiogenesis. These results demonstrate critical roles of IP6K1-generated 5-InsP7 in regulating focal adhesion dynamics and actin cytoskeleton remodeling and reveal functional mechanisms by which itraconazole inhibits cell motility.
Le texte complet de cet article est disponible en PDF.Highlights |
• | IP6K1 binds Arp2 and generates 5-InsP7 to recruit coronin to Arp2/3 complex. |
• | IP6K1 generates 5-InsP7 in focal adhesion to promote FAK dimerization. |
• | Itraconazole inhibits Arp2/3 complex by enhancing the binding of IP6K1 to Arp2. |
• | Itraconazole lowers FAK phosphorylation by removing IP6K1 from focal adhesion. |
• | Itraconazole disrupts 5-InsP7-mediated focal adhesion and cytoskeletal dynamics. |
Abbreviations : IP6K1, 5-InsP7, Arp2/3, FAK, 5-PCP, CF2, HUVECs, MEF
Keywords : Itraconazole, IP6K, Inositol pyrophosphate, FAK, α-actinin, Arp2/3
Plan
Vol 161
Article 114449- mai 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?